Literature DB >> 15345878

Acute lung injury and acute respiratory distress syndrome.

Anil Vasudevan1, Rakesh Lodha, S K Kabra.   

Abstract

Acute lung injury and acute respiratory distress syndrome are an important challenge for pediatric intensive care units. These disorders are characterized by a significant inflammatory response to a local (pulmonary) or remote (systemic) insult resulting in injury to alveolar epithelial and endothelial barriers of the lung, acute inflammation and protein rich pulmonary edema. The reported rates in children vary from 8.5 to 16 cases / 1000 pediatric intensive care unit (PICU) admissions. The pathological features of ARDS are described as passing through three overlapping phases - an inflammatory or exudative phase (0-7 days), a proliferative phase (7-21 days) and lastly a fibrotic phase (from day 10). The treatment of ARDS rests on good supportive care and control of initiating cause. The goal of ventilating patients with ALI/ARDS should be to maintain adequate gas exchange with minimal ventilator induced lung injury. This can be achieved by use of optimum PEEP, low tidal volume and appropriate FiO2. High frequency ventilation can improve oxygenation but does affect the outcomes. Prone positioning is a useful strategy to improve oxygenation. Pharmacological strategies have not made any significant impact on the outcomes. Preliminary data suggests some role for use of corticosteroids in non-resolving ARDS. The mortality rates have declined over the last decade chiefly due to the advances in supporting critically ill patients.

Entities:  

Mesh:

Year:  2004        PMID: 15345878     DOI: 10.1007/bf02730667

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  75 in total

Review 1.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.

Authors:  G R Bernard; A Artigas; K L Brigham; J Carlet; K Falke; L Hudson; M Lamy; J R Legall; A Morris; R Spragg
Journal:  Am J Respir Crit Care Med       Date:  1994-03       Impact factor: 21.405

2.  Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome.

Authors:  L Armstrong; A B Millar
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

3.  An expanded definition of the adult respiratory distress syndrome.

Authors:  J F Murray; M A Matthay; J M Luce; M R Flick
Journal:  Am Rev Respir Dis       Date:  1988-09

4.  Endothelin-1 in adult respiratory distress syndrome.

Authors:  W Druml; H Steltzer; W Waldhäusl; K Lenz; A Hammerle; H Vierhapper; S Gasic; O F Wagner
Journal:  Am Rev Respir Dis       Date:  1993-11

5.  Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups.

Authors:  S C Donnelly; R M Strieter; S L Kunkel; A Walz; C R Robertson; D C Carter; I S Grant; A J Pollok; C Haslett
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

6.  Prospective, randomized comparison of high-frequency oscillatory ventilation and conventional mechanical ventilation in pediatric respiratory failure.

Authors:  J H Arnold; J H Hanson; L O Toro-Figuero; J Gutiérrez; R J Berens; D L Anglin
Journal:  Crit Care Med       Date:  1994-10       Impact factor: 7.598

7.  Clinical risks for development of the acute respiratory distress syndrome.

Authors:  L D Hudson; J A Milberg; D Anardi; R J Maunder
Journal:  Am J Respir Crit Care Med       Date:  1995-02       Impact factor: 21.405

Review 8.  Pulmonary fibrosis: cytokines in the balance.

Authors:  R K Coker; G J Laurent
Journal:  Eur Respir J       Date:  1998-06       Impact factor: 16.671

Review 9.  Anticatabolic and anabolic strategies in critical illness: a review of current treatment modalities.

Authors:  D W Chang; L DeSanti; R H Demling
Journal:  Shock       Date:  1998-09       Impact factor: 3.454

10.  Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury.

Authors:  I Y Haddad; G Pataki; P Hu; C Galliani; J S Beckman; S Matalon
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more
  7 in total

Review 1.  Ventilatory strategies and adjunctive therapy in ARDS.

Authors:  Ajay R Desai; Akash Deep
Journal:  Indian J Pediatr       Date:  2006-08       Impact factor: 1.967

2.  Lugrandoside attenuates LPS-induced acute respiratory distress syndrome by anti-inflammation and anti-apoptosis in mice.

Authors:  Chengbao Li; Ying Huang; Xueya Yao; Baoji Hu; Suzhen Wu; Guannan Chen; Xin Lv; Fubo Tian
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 3.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

4.  Deletion of caveolin-1 protects hyperoxia-induced apoptosis via survivin-mediated pathways.

Authors:  Meng Zhang; Ling Lin; Seon-Jin Lee; Li Mo; Jiaofei Cao; Emeka Ifedigbo; Yang Jin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-09-18       Impact factor: 5.464

5.  Elucidating the fuzziness in physician decision making in ARDS.

Authors:  David B Bernstein; Binh Nguyen; Gilman B Allen; Jason H T Bates
Journal:  J Clin Monit Comput       Date:  2013-03-06       Impact factor: 2.502

6.  Effects of ischemic acute kidney injury on lung water balance: nephrogenic pulmonary edema?

Authors:  Rajit K Basu; Derek Wheeler
Journal:  Pulm Med       Date:  2011-05-24

7.  Acute respiratory distress syndrome: a life threatening associated complication of SARS-CoV-2 infection inducing COVID-19.

Authors:  Riadh Badraoui; Mousa M Alrashedi; Michèle Véronique El-May; Fevzi Bardakci
Journal:  J Biomol Struct Dyn       Date:  2020-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.